16
Jun
2027
National Exhibition and Convention Center
16 Jun 2027 - 18 Jun 2027
stand 62F56b
9
Nov
2027
Messe, Frankfurt
9 - 11 November 2027
stand 80J24

Hangzhou Jiuyuan Genetic Biopharmaceutic

About Hangzhou Jiuyuan Genetic Biopharmaceutic

We are a leading biopharmaceutical company firstly developed the following products in China: rhG-CSF (filgrastim), Pegfilgrastim, Liraglutide(recombinant),Enoxaparin sodium, Fulvestrant, Interleukin-11, Palonosetron Hydrochloride, rhBMP-2 , Fosaprepitant dimeglumine. Our product pipeline include: Semaglutide (recombinant), Recombinant Hyaluronidase,  Avatrombopag maleate, Bone repair material with rhBMP-2 - Bone repair, Romosozumab,Daratumumab, Emicizumab, Amylin analog, SIRPα- specific monoclonal antibody.

Certifications
  • CE
    CE
  • FDA
    FDA
  • GMP
    GMP
  • ISO
    ISO
  • Other

Meet us at

  • CPHI & PMEC China 2027

    National Exhibition and Convention Center
    16 Jun 2027 - 18 Jun 2027
    stand 62F56b
  • CPHI Frankfurt 2027

    Messe, Frankfurt
    9 - 11 November 2027
    stand 80J24
  • Country/Region:
    China
  • On CPHI since:
    2015
  • Certificates:
    5
  • Employees:
    1000 - 4999
Company types
Manufacturer/Innovator
Contact info

Products from Hangzhou Jiuyuan Genetic Biopharmaceutic (20)